Enliven Therapeutics Q2 net loss $32.5M; positive Phase 1 data for ELVN-001 in CML; cash $895M into 2030

Enliven Therapeutics, Inc.

Net loss of $32.5M for Q2 2026 vs $25.3M in Q2 2025; R&D expenses $29.0M.
Cash, cash equivalents and marketable securities of $895.2M as of June 30, 2026, expected to fund operations into 2030.
ELVN-001 Phase 1 data: 61% overall MMR, 48% MMR by 24 weeks in 80mg QD cohort; favorable safety profile.
FDA alignment on Phase 3 ENABLE-2 trial design; 80mg QD selected as recommended dose; Fast Track Designation granted.
Expect to initiate ENABLE-2 Phase 3 trial in H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.